Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Xian-Janssen To Continue Duragesic Sale In China

This article was originally published in PharmAsia News

Executive Summary

Xian-Janssen, Janssen's subsidiary and agent of Duragesic skin patches in China, announced it had no plans for local recall of the painkiller, which recently received a U.S. FDA alert on possible death and life-threatening side effects related to improper use. To date, the company's head office has not given any updates regarding revised usage of the drug in China. Xian-Janssen emphasized that Duragesic is safe and effective for relieving moderate and severe chronic pain, but users should follow closely the instructions on usage under a doctor's supervision. (Click here for more)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts